Matthew D. Evison

Dr. Matthew D. Evison

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Thorax
Verified
Journal Article
Closed access
MRMark E Roberts
Mark E Roberts
NRNajib Rahman
Najib Rahman
NMNick A Maskell
Nick A Maskell
ABAnna C Bibby
Anna C Bibby
KBKevin G Blyth
Kevin G Blyth
BGBTS Pleural Guideline Development Group
BTS Pleural Guideline Development Group

8 August 2023 in Thorax
Verified
Journal Article
Closed access
PDF file
MRMark E Roberts
Mark E Roberts
NRNajib Rahman
Najib Rahman
NMNick A Maskell
Nick A Maskell
ABAnna C Bibby
Anna C Bibby
KBKevin G Blyth
Kevin G Blyth
SWSteven Walker
Steven Walker
The aim of the guideline was to provide evidence-based guidance on the investigation and management of pleural disease. Pleural disease is common and represents a major and rapidly developing subspecialty that presents to many different hospital services. Since the last BTS Guideline for pleural disease published in 2010,3–9 many high quality and practice changing studies, using patient centred outcomes, have been published. The paradigms for the investigation and management of pleural disease have therefore shifted, so this guideline aimed to capture this evidence and use it to answer the most important questions relevant to today’s practice.

1 December 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
OLon behalf of AstraZeneca UK Limited
on behalf of AstraZeneca UK Limited
MEMatthew D. Evison
Matthew D. Evison
For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease. Although curable, stage III NSCLC encompasses a diverse range of disease presentation, with an equally complex range of multi-modal treatment options, including systemic and local therapies for distant and local disease control, respectively. This complexity results in a number of challenges for the multi-disciplinary team (MDT) in achieving optimal treatment outcomes for patients. As multi-modality treatment is the preferred treatment strategy for all stage III disease, the focus of this article is the key surgical, chemotherapy and radiotherapy clinical trials as well as guidelines that currently outline radical therapy options for patients with both potentially resectable and unresectable stage III NSCLC.

19 May 2020 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
ASAndrew E Stanton
Andrew E Stanton
AEAnthony Edey
Anthony Edey
MEMatthew D. Evison
Matthew D. Evison
IFIan Forrest
Ian Forrest
SHSabrine Hippolyte
Sabrine Hippolyte
JPJohn E S Park
John E S Park
Introduction The British Thoracic Society (BTS) responded to a call from the pleural community to establish this new Training Standard to detail the capabilities in practice for thoracic ultrasound (TUS), which will build on the previous curricula and extend the remit to include training for the emergency provision of TUS. Methods BTS convened a working group to produce a set of Training Standards. Results This document provides a comprehensive Training Standard for TUS facilitating timely and improved management of patients with respiratory presentations, particularly (but not exclusively) pleural pathologies. Discussion The Training Standards document will be widely disseminated.

1 July 2019 in Lung Cancer
Verified
Journal Article
Closed access
STSelina Tsim
Selina Tsim
SPSarah Paterson
Sarah Paterson
DCDouglas Cartwright
Douglas Cartwright
CFChristopher J. Fong
Christopher J. Fong
LALaura Alexander
Laura Alexander
KBKevin G. Blyth
Kevin G. Blyth

1 August 2019 in Lung Cancer
Verified
Journal Article
Closed access
HBHaval Balata
Haval Balata
MEMatthew D. Evison
Matthew D. Evison
ASAnna Sharman
Anna Sharman
PCPhil Crosbie
Phil Crosbie
RBRichard Booton
Richard Booton